ArticleVirology2007
Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse.
Article in Virology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 74 citations in OpenAlex.
- Monoclonal antibody therapeutics for infectious diseases: Beyond normal human immunoglobulin.Pharmacology & therapeutics · 2022Review
- CXCL12 and CXCL13 Cytokine Serum Levels Are Associated with the Magnitude and the Quality of SARS-CoV-2 Humoral Responses.Viruses · 2022Article
- Neutralizing monoclonal antibodies against highly pathogenic coronaviruses.Current opinion in virology · 2022Review
- Analysis of B Cell Receptor Repertoires Reveals Key Signatures of the Systemic B Cell Response after SARS-CoV-2 Infection.Journal of virology · 2022Article
- A Patent Review on the Therapeutic Application of Monoclonal Antibodies in COVID-19.International journal of molecular sciences · 2021Review
- COVID-19 pandemic: lessons learned from more than a century of pandemics and current vaccine development for pandemic control.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Review
- Cross-neutralization of RBD mutant strains of SARS-CoV-2 by convalescent patient derived antibodies.Biotechnology journal · 2021Article
- Review
- Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2.International journal of biological macromolecules · 2021Review
- Immunological mechanisms of vaccine-induced protection against COVID-19 in humans.Nature reviews. Immunology · 2021Review
- Development of Coronavirus Treatments Using Neutralizing Antibodies.Microorganisms · 2021Review
- The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews · 2021Review
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard.PloS one · 2021Article
- COVID-19: Diagnostics, Therapeutic Advances, and Vaccine Development.Current clinical microbiology reports · 2021Review
- Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview.Immunologic research · 2020Review
- Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities.Journal of medicinal chemistry · 2020Review
- In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins.Journal of proteome research · 2020Article
- Immunotherapeutic approaches to curtail COVID-19.International immunopharmacology · 2020Review
- Human B Cell Clonal Expansion and Convergent Antibody Responses to SARS-CoV-2.Cell host & microbe · 2020Article
- Immunological considerations for COVID-19 vaccine strategies.Nature reviews. Immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Passive therapy with neutralizing human monoclonal antibodies (mAbs) could be an effective therapy against severe acute respiratory syndrome coronavirus (SARS-CoV). Utilizing the human immunoglobulin transgenic mouse, XenoMouse, we produced fully human SARS-CoV spike (S) protein specific antibodies. Antibodies were examined for reactivity against a recombinant S1 protein, to which 200 antibodies reacted. Twenty-seven antibodies neutralized 200TCID(50) SARS-CoV (Urbani). Additionally, 57 neutralizing antibodies were found that are likely specific to S2. Mapping of the binding region was achieved with several S1 recombinant proteins. Most S1 reactive neutralizing mAbs bound to the RBD, aa 318-510. However, two S1 specific mAbs reacted with a domain upstream of the RBD between aa 12 and 261. Immunoglobulin gene sequence analyses suggested at least 8 different binding specificities. Unique human mAbs could be used as a cocktail that would simultaneously target several neutralizing epitopes and prevent emergence of escape mutants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.